Literature DB >> 7296487

Hypercalcemia in carcinoma of the breast without evidence of bone destruction: beneficial effect of hormonal therapy.

M Sztern, A Barkan, E Rakowsky, R Shainkin-Kestenbaum, R Marilus, I Blum.   

Abstract

A premenopausal woman with soft tissue metastases from a carcinoma of the breast developed hypercalcemia with hypophosphatemia, reduced tubular reabsorption of phosphate, elevated urinary cyclic AMP levels and normal serum PTH levels was observed. Hormonal therapy with testosterone followed by tamoxifen induced normalization of her serum calcium concomitant with the disappearance of the pleural effusion and reduction in the size of her lung metastases. The correlation between the efficacy of antitumor treatment on pleural effusion, lung metastases, and normalization of serum calcium, as well as the elevated PTH level in the pleural effusion, suggest that this breast carcinoma secreted a PTH-like substance.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7296487     DOI: 10.1002/1097-0142(19811201)48:11<2383::aid-cncr2820481108>3.0.co;2-n

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  4 in total

1.  Tamoxifen flare hypercalcemia: an additional support for gallium nitrate usage.

Authors:  Govinda Pillai Arumugam; Sengoden Sundravel; Palanivel Shanthi; Panchanadham Sachdanandam
Journal:  J Bone Miner Metab       Date:  2006       Impact factor: 2.626

2.  Renal handling of calcium and sodium in metastatic and non-metastatic malignancy.

Authors:  J A Kanis; R C Percival; G H Urwin; S A Murray; N A Hamdy; A J Yates
Journal:  Br Med J (Clin Res Ed)       Date:  1986-05-10

3.  Mechanism of malignant hypercalcaemia in carcinoma of the breast.

Authors:  R C Percival; A J Yates; R E Gray; J Galloway; K Rogers; F E Neal; J A Kanis
Journal:  Br Med J (Clin Res Ed)       Date:  1985-09-21

4.  Hypercalcemia in breast cancer.

Authors:  G Francini; R Petrioli; E Maioli; S Gonnelli; S Marsili; A Aquino; S Bruni
Journal:  Clin Exp Metastasis       Date:  1993-09       Impact factor: 5.150

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.